Cargando…
Immunological and hematological effects of IL‐5(Rα)‐targeted therapy: An overview
IL‐5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. Hence, IL‐5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophi...
Autores principales: | Hassani, M., Koenderman, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220846/ https://www.ncbi.nlm.nih.gov/pubmed/29611207 http://dx.doi.org/10.1111/all.13451 |
Ejemplares similares
-
Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
por: Crisci, Stefania, et al.
Publicado: (2019) -
Targeting IL-2: an unexpected effect in treating immunological diseases
por: Ye, Congxiu, et al.
Publicado: (2018) -
Adverse hematological effects of hexavalent chromium: an overview
por: Ray, Rina Rani
Publicado: (2016) -
Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020) -
Cardiotoxicity of Novel Targeted Hematological Therapies
por: Giudice, Valentina, et al.
Publicado: (2020)